Brincidofovir: Phase III started

Chimerix began the double-blind, placebo-controlled, U.S. Phase III SUPPRESS trial to evaluate 100 mg oral brincidofovir twice weekly in about 450 CMV-seropositive hematopoietic stem cell transplant (...